Oxford Biomedica PLC Logo

Oxford Biomedica PLC

A global CDMO specializing in cell and gene therapy and viral vector manufacturing.

OXB | IL

Overview

Corporate Details

ISIN(s):
GB00BDFBVT43
LEI:
213800S1GVQNXQ15K851
Country:
United Kingdom
Address:
WINDRUSH COURT, OX4 6LT OXFORD

Description

Oxford Biomedica (OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. A pioneer in the field, the company has extensive experience in viral vectors, the enabling technology for many advanced therapies. OXB provides end-to-end services to pharmaceutical and biotechnology partners, supporting programs from preclinical development through to commercial launch. Its core expertise includes the development and GMP manufacturing of various vector types, including lentivirus, adeno-associated virus (AAV), and adenovirus. The company offers proprietary technologies like its LentiVector™ platform, the first commercially approved lentiviral system, and its inAAVate™ platform for AAV, in addition to tech-transfer capabilities.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2018-05-02 09:00
Kymriah receives FDA approval for DLBCL
English 16.0 KB
2018-05-01 11:37
Total Voting Rights
English 14.2 KB
2018-04-26 17:33
Holding(s) in Company
English 67.5 KB
2018-04-25 02:00
2017 Notice of AGM
English 506.7 KB
2018-04-11 16:11
Director Dealings / Market Share Purchase
English 24.3 KB
2018-04-09 19:39
Director/PDMR Shareholding
English 31.2 KB
2018-04-09 12:47
Director/PDMR Shareholding
English 24.2 KB
2018-04-05 14:08
Director/PDMR Shareholding
English 17.4 KB
2018-04-03 11:45
Total Voting Rights
English 14.2 KB
2018-03-22 12:05
Director/PDMR Shareholding
English 17.8 KB
2018-03-20 08:15
Hardman & Co Res: Supply to meet demand
English 12.6 KB
2018-03-15 08:01
Board Change
English 19.8 KB
2018-03-15 08:01
Preliminary Results
English 315.9 KB
2018-03-09 19:41
Result of Placing
English 23.3 KB
2018-03-09 16:42
PROPOSED PLACING TO RAISE APPROXIMATELY £20.5M
English 119.0 KB

Automate Your Workflow. Get a real-time feed of all Oxford Biomedica PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oxford Biomedica PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oxford Biomedica PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Aprogen, Inc Logo
Develops and manufactures biologic medicines, including biosimilars and novel drugs.
South Korea
007460
Develops drugs for intractable diseases by regulating oxidative stress and CAFs.
South Korea
293780
Aptamer Sciences Inc Logo
Clinical-stage company developing aptamer-based therapeutics for oncology.
South Korea
291650
Aptorum Group Ltd Logo
Clinical-stage biopharma developing therapeutics for oncology and infectious diseases.
United States of America
APM
Aquestive Therapeutics, Inc. Logo
Pharmaceutical company developing oral film medicines for CNS and allergic reactions.
United States of America
AQST
Arbutus Biopharma Corp Logo
Clinical-stage biopharma company developing a functional cure for chronic Hepatitis B.
United States of America
ABUS
Arcellx, Inc. Logo
A clinical-stage biotech company developing immunotherapies for cancer and autoimmune diseases.
United States of America
ACLX
Arctic Bioscience Logo
Develops pharmaceutical and nutraceutical products from marine membrane lipids.
Norway
ABS
ArcticZymes Technologies Logo
Develops and manufactures novel recombinant enzymes from Arctic marine organisms.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
A commercial-stage mRNA medicines company focused on rare and infectious diseases.
United States of America
ARCT

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.